{"id":22899,"date":"2026-06-29T13:14:32","date_gmt":"2026-06-29T13:14:32","guid":{"rendered":"https:\/\/drtaherabuhejleh.com\/?page_id=22899"},"modified":"2026-06-30T10:55:45","modified_gmt":"2026-06-30T10:55:45","slug":"publications","status":"publish","type":"page","link":"https:\/\/drtaherabuhejleh.com\/ar\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"\n

1. Abdeljalil RA, Al-Odwan A, Alshwayyat S, Nemrawi LO, Taher Abu Hejleh<\/strong>, Alrabi K, Yaser S, Jazar HA, Khader J, Al-Nsour A, Haddad H, Jalil RA. Multimodality approach for locally advanced lung cancer: when is surgery most beneficial?. J Cardiothorac Surg<\/em>. 2025;20(1):473. PMID 41430277<\/a><\/p>\n\n\n\n

2. Cortellini A, Garbo E, La Cava G, Citarella F, Santo V, Brunetti L, Pinato DJ, Naidoo J, Loza M, Genova C, et al, Taher Abu Hejleh<\/strong>, et al. Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression \u2265 50%, and poor performance status: Transformer-based AI to characterize prognostic complexity. Lung Cancer<\/em>. 2025;209:108799. PMID 41108882<\/a><\/p>\n\n\n\n

3. Cortellini A, Santo V, Brunetti L, Garbo E, Pinato DJ, La Cava G, Naidoo J, Katz A, Loza M, Neal JW, et al, Taher Abu Hejleh<\/strong>, et al. Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 \u226550%: insights from the pembrolizumab 5-year global registry. J Immunother Cancer<\/em>. 2025;13(9). PMID 41022528<\/a><\/p>\n\n\n\n

4. Al-Rabi K, El Khatib O, Abdeljalil R, Talab Y, Alnsour A, Khader J, Al-Showbaki L, Awidi A, Al-Fararjeh F, Yaser S, Taher Abu Hejleh<\/strong>, Jazar HA, Haddad H, Mahmoud N, Zayed A, Yaseen A, Al-Batsh T, Shamieh O, Al Ibrahim A, Abdel-Razeq H, Obeidat N. Lung Cancer in Jordan. J Thorac Oncol<\/em>. 2025;20(8):1007-1017. PMID 40769630<\/a><\/p>\n\n\n\n

5. Abu Taha S, Taher Abu Hejleh<\/strong>, ElHaddad M, Al-Ibraheem A, Abbasi A, Sumaida A, Bushehri A, Mostafa A, Youssef B, Alotain I, et al. Chemotherapy-free innovations in locally advanced head and neck cancer: a comprehensive review. Front Oncol<\/em>. 2025;15:1552337. PMID 40330829<\/a><\/p>\n\n\n\n

6. Cortellini A, Brunetti L, Di Fazio GR, Garbo E, Pinato DJ, Naidoo J, Katz A, Loza M, Neal JW, Genova C, et al, Taher Abu Hejleh<\/strong>, et al. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1\u226550% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. J Immunother Cancer<\/em>. 2025;13(2). PMID 39904562<\/a><\/p>\n\n\n\n

7. Abu Taha S, Taher Abu Hejleh<\/strong>, Wahbeh L, Alzibdeh A, Berawi M, Qambar M, Mukahal M, Abuhijla F, Abu-Hijlih R, Taqash A, Hussein T, Alrousan M, Saraireh OA, Al-Gargaz W, Al-Ibraheem A, Ghatasheh H, Hosni A, Mohamad I. Clinical outcomes and impact of prognostic factors in resectable oral cavity squamous cell carcinoma. Front Oncol<\/em>. 2024;14:1443367. PMID 39464708<\/a><\/p>\n\n\n\n

8. Byrne MM, Sutamtewagul G, Zeitler W, Mott SL, Zamba GKD, Kojadinovic A, Zhang J, Taher Abu Hejleh<\/strong>, Clamon G, Furqan M. Phase II study of nab-paclitaxel with gemcitabine for relapsed\/refractory small cell lung cancer. Front Oncol<\/em>. 2024;14:1303268. PMID 39144826<\/a><\/p>\n\n\n\n

9. Saleh Y, Taher Abu Hejleh<\/strong>, Abdelrahim M, Shamseddine A, Chehade L, Alawabdeh T, Mohamad I, Sammour M, Turfa R. Hepatocellular Carcinoma: The Evolving Role of Systemic Therapies as a Bridging Treatment to Liver Transplantation. Cancers (Basel)<\/em>. 2024;16(11). PMID 38893200<\/a><\/p>\n\n\n\n

10. Taher Abu Hejleh<\/strong>, AlSawalha K, Abdel Hafiz S, Al-Batsh T, Abu Hejleh R, Yaser S, Abu Jazar H, Khader J, Alnsour A, Mohamad I, Abdel Jalil R, Abu-Shanab A, Gharaibeh A, Abu Shattal M, Alibraheem A, Haddad H, Mahmoud N, Obeidat S, Al-Jaghbeer MJ, Furqan M, Cortellini A, Velcheti V, Al-Rabi K. Beyond clinical trials: real-world impact of immunotherapy on NSCLC in Jordan. Front Oncol<\/em>. 2024;14:1369126. PMID 38746680<\/a><\/p>\n\n\n\n

11. Mansour A, Obeidat S, Al-Adhami D, Taher Abu Hejleh<\/strong>, Al-Ibraheem A. Gallium-68-Labeled Fibroblast Activation Protein Inhibitor as an Alternative Radiotracer to Fluorine 18-Fluorodeoxyglucose: A Case Report of Rare Pulmonary Colloid Adenocarcinoma Diagnosed by PET\/CT. Cureus<\/em>. 2024;16(3):e56173. PMID 38618464<\/a><\/p>\n\n\n\n

12. Mohamad I, Taher Abu Hejleh<\/strong>, Qandeel M, Al-Hussaini M, Koro S, Taqash A, Almousa A, Abuhijla F, Abuhijlih R, Ajlouni F, Al-Ibraheem A, Laban DA, Hussein T, Mayta E, Al-Gargaz W, Hosni A. Concordance between head and neck MRI and histopathology in detecting laryngeal subsite invasion among patients with laryngeal cancer. Cancer Imaging<\/em>. 2023;23(1):99. PMID 37858162<\/a><\/p>\n\n\n\n

13. Al-Ibraheem A, Abdlkadir AS, Al-Adhami D, Taher Abu Hejleh<\/strong>, Mansour A, Mohamad I, Juweid ME, Al-Rasheed U, Al-Hajaj N, Laban DA, Estrada-Lobato E, Saraireh O. The Prognostic and Diagnostic Value of [18F]FDG PET\/CT in Untreated Laryngeal Carcinoma. J Clin Med<\/em>. 2023;12(10). PMID 37240619<\/a><\/p>\n\n\n\n

14. Mohamad I, Taher Abu Hejleh<\/strong>, Abdelqader S, Wahbeh L, Taqash A, Almousa A, Mayta E, Al-Ibraheem A, Abuhijla F, Abu-Hijlih R, Hussein T, Al-Gargaz W, Ghatasheh H, Hosni A. Re-Irradiation for Recurrent Head and Neck Cancer: Freedom from Cancer Recurrence Rate. J Clin Med<\/em>. 2023;12(8). PMID 37109315<\/a><\/p>\n\n\n\n

15. Jonsdottir G, Smith M, Wood S, Taher Abu Hejleh<\/strong>, Furqan M. Activity of osimertinib in a patient with stage IV non-small cell lung cancer harboring HER2 exon 19, p.L755P mutation: case report. Transl Lung Cancer Res<\/em>. 2023;12(4):927-932. PMID 37197637<\/a><\/p>\n\n\n\n

16. Anyidoho PA, Verschraegen CF, Markham MJ, Alberts S, Sweetenham J, Cameron K, Taher Abu Hejleh<\/strong>. Impact of the Immediate Release of Clinical Information Rules on Health Care Delivery to Patients With Cancer. JCO Oncol Pract<\/em>. 2023;19(5):e706-e713. PMID 36780583<\/a><\/p>\n\n\n\n

17. Ardeshir-Larijani F, Althouse SK, Leal T, Feldman LE, Taher Abu Hejleh<\/strong>, Patel M, Gentzler RD, Miller AR, Hanna NH. A Phase II Trial of Atezolizumab Plus Carboplatin Plus Pemetrexed Plus Bevacizumab in the Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer: Big Ten Cancer Research Consortium (BTCRC)-LUN 17-139. Clin Lung Cancer<\/em>. 2022;23(7):578-584. PMID 36041949<\/a><\/p>\n\n\n\n

18. Furqan M, Taher Abu Hejleh<\/strong>, Stephens LM, Hartwig SM, Mott SL, Pulliam CF, Petronek M, Henrich JB, Fath MA, Houtman JC, et al. Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer. Redox Biol<\/em>. 2022;53:102318. PMID 35525024<\/a><\/p>\n\n\n\n

19. Abuelbeh I, Abu-Shawer O, Abu-Shawer M, Alkderat M, Safi M, Alwazani A, Alkhatib A, Abu-Hussain B, Aladawi M, Ismail S, Altamimi T, Taher Abu Hejleh<\/strong>. The Predictive Value of Peripheral Immune Cell Counts for the Presence of Brain Metastases in Stage IV Non-Small-Cell Lung Cancer (NSCLC). Avicenna J Med<\/em>. 2022;12(2):67-72. PMID 35833159<\/a><\/p>\n\n\n\n

20. Field MG, Boldt HC, Taher Abu Hejleh<\/strong>, Binkley EM. Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer. Am J Ophthalmol Case Rep<\/em>. 2022;26:101459. PMID 35265776<\/a><\/p>\n\n\n\n

21. Mohamad I, Abu-Hijleh F, Mayta E, Taher Abu Hejleh<\/strong>, Al-Gargaz W, Al Mousa A, Abu-Hijlih R, Hosni A. Comparison of Two Standard Treatment Approaches in Locoregionally Advanced Nasopharyngeal Carcinoma. South Asian J Cancer<\/em>. 2022;11(3):223-228. PMID 36588606<\/a><\/p>\n\n\n\n

22. An J, Yan M, Yu N, Chennamadhavuni A, Furqan M, Mott SL, Loeffler BT, Kruser T, Sita TL, Feldman L, Nguyen R, Pasquinelli M, Hanna NH, Taher Abu Hejleh<\/strong>. Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation. Transl Lung Cancer Res<\/em>. 2021;10(8):3608-3615. PMID 34584860<\/a><\/p>\n\n\n\n

23. Chau J, Yadav M, Liu B, Furqan M, Dai Q, Shahi S, Gupta A, Mercer KN, Eastman E, Taher Abu Hejleh<\/strong>, Chan C, Weiner GJ, Cherwin C, Lee STM, Zhong C, Mangalam A, Zhang J. Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer. BMC Cancer<\/em>. 2021;21(1):808. PMID 34256732<\/a><\/p>\n\n\n\n

24. Safi D, Taher Abu Hejleh<\/strong>, Furqan M. Narrative review: mesenchymal-epithelial transition inhibitors-meeting their target. Transl Lung Cancer Res<\/em>. 2021;10(1):462-474. PMID 33569327<\/a><\/p>\n\n\n\n

25. Clamon G, Zeitler W, An J, Taher Abu Hejleh<\/strong>. Transformational Changes Between Non-Small Cell and Small Cell Lung Cancer-Biological and Clinical Relevance-A Review. Am J Clin Oncol<\/em>. 2020;43(9):670-675. PMID 32889839<\/a><\/p>\n\n\n\n

26. Taher Abu Hejleh<\/strong>, Furqan M, Ballas Z, Clamon G. The clinical significance of soluble PD-1 and PD-L1 in lung cancer. Crit Rev Oncol Hematol<\/em>. 2019;143:148-152. PMID 31675543<\/a><\/p>\n\n\n\n

27. Furqan M, Tien YY, Schroeder MC, Parekh KR, Keech J, Allen BG, Thomas A, Zhang J, Clamon G, Taher Abu Hejleh<\/strong>. Lobar versus sub-lobar surgery for pulmonary typical carcinoid, a population-based analysis. J Thorac Dis<\/em>. 2018;10(10):5850-5859. PMID 30505493<\/a><\/p>\n\n\n\n

28. Abdel-Razeq H, Barbar M, Taher Abu Hejleh<\/strong>, Mansour A. Cancer care for adolescents and young adults in Jordan. East Mediterr Health J<\/em>. 2018;24(7):687-695. PMID 30215479<\/a><\/p>\n\n\n\n

29. Taher Abu Hejleh<\/strong>, Abushahin L, Keech J, Allen BG, Parekh KR, Furqan M, Iannettoni M, Zamba GKD, Mott SL, Clamon G. Screening Patients with Esophageal Cancer to Determine Eligibility for Adjuvant Treatment Trials. Anticancer Res<\/em>. 2018;38(9):5247-5251. PMID 30194174<\/a><\/p>\n\n\n\n

30. Swami U, Lenert P, Furqan M, Taher Abu Hejleh<\/strong>, Clamon G, Zhang J. Atezolizumab after Nivolumab-Induced Inflammatory Polyarthritis: Can Anti-PD-L1 Immunotherapy Be Administered after Anti-PD-1-Related Immune Toxicities?. J Thorac Oncol<\/em>. 2018;13(6):e102-e103. PMID 29793647<\/a><\/p>\n\n\n\n

31. Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Taher Abu Hejleh<\/strong>, Berg DJ, Zhang J, Keech J, Parekh KR, et al. O2- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell<\/em>. 2017;32(2):268. PMID 28810149<\/a><\/p>\n\n\n\n

32. Plichta K, Camden N, Furqan M, Taher Abu Hejleh<\/strong>, Clamon GH, Zhang J, Flynn RT, Bhatia SK, Smith MC, Buatti JM, Allen BG. SBRT to adrenal metastases provides high local control with minimal toxicity. Adv Radiat Oncol<\/em>. 2017;2(4):581-587. PMID 29204525<\/a><\/p>\n\n\n\n

33. Mapuskar KA, Flippo KH, Schoenfeld JD, Riley DP, Strack S, Taher Abu Hejleh<\/strong>, Furqan M, Monga V, Domann FE, Buatti JM, Goswami PC, Spitz DR, Allen BG. Mitochondrial Superoxide Increases Age-Associated Susceptibility of Human Dermal Fibroblasts to Radiation and Chemotherapy. Cancer Res<\/em>. 2017;77(18):5054-5067. PMID 28765155<\/a><\/p>\n\n\n\n

34. Mohamad I, Salem A, Taher Abu Hejleh<\/strong>, Wadi-Ramahi S, Qandeel M, El Khatib S, Asha W, Mhied S, Al Saraireh O, Al-Gargaz W, Abdulelah H, Hosni A, Al Mousa A. Peer-assisted Learning: Intensity-modulated Radiotherapy Transition in Developing Countries. Clin Oncol (R Coll Radiol)<\/em>. 2017;29(10):689-695. PMID 28647432<\/a><\/p>\n\n\n\n

35. Zahra A, Fath MA, Opat E, Mapuskar KA, Bhatia SK, Ma DC, Rodman SN, Snyders TP, Chenard CA, Eichenberger-Gilmore JM, Bodeker KL, Ahmann L, Smith BJ, Vollstedt SA, Brown HA, Taher Abu Hejleh<\/strong>, Clamon GH, Berg DJ, Szweda LI, Spitz DR, Buatti JM, Allen BG. Consuming a Ketogenic Diet while Receiving Radiation and Chemotherapy for Locally Advanced Lung Cancer and Pancreatic Cancer: The University of Iowa Experience of Two Phase 1 Clinical Trials. Radiat Res<\/em>. 2017;187(6):743-754. PMID 28437190<\/a><\/p>\n\n\n\n

36. Schoenfeld JD, Sibenaller ZA, Mapuskar KA, Wagner BA, Cramer-Morales KL, Furqan M, Sandhu S, Carlisle TL, Smith MC, Taher Abu Hejleh<\/strong>, Berg DJ, Zhang J, Keech J, Parekh KR, et al. O2- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell<\/em>. 2017;31(4):487-500. PMID 28366679<\/a><\/p>\n\n\n\n

37. Chiappori AA, Otterson GA, Dowlati A, Traynor AM, Horn L, Owonikoko TK, Ross HJ, Hann CL, Taher Abu Hejleh<\/strong>, Nieva J, Zhao X, Schell M, Sullivan DM. A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer. Oncologist<\/em>. 2016;21(10):1163-1164. PMID 27694157<\/a><\/p>\n\n\n\n

38. Zahra A, Chang T, Taher Abu Hejleh<\/strong>, Furqan M, Clamon GH, Bhatia SK, Watkins JM, Mott SL, Ahmann LL, Bodeker KL, Spitz DR, Buatti JM, Allen BG. Once Daily High-dose Radiation (>=60 Gy) Treatment in Limited Stage Small Cell Lung Cancer. J Oncol Transl Res<\/em>. 2016;2(1). PMID 27981260<\/a><\/p>\n\n\n\n

39. Schroeder MC, Chapman CG, Nattinger MC, Halfdanarson TR, Taher Abu Hejleh<\/strong>, Tien YY, Brooks JM. Variation in geographic access to chemotherapy by definitions of providers and service locations: a population-based observational study. BMC Health Serv Res<\/em>. 2016;16:274. PMID 27430623<\/a><\/p>\n\n\n\n

40. Taher Abu Hejleh<\/strong>, Chrischilles EA, Halfdanarson TR, Simon C, Pendergast JF, Jiang D, Smith CJ, Porter AT, Carter KD, Wallace RB, Cancer Care Outcomes Research and Surveillance Consortium (CanCORS). The Effect of Receiving Treatment Within a Clinical Trial Setting on Survival and Quality of Care Perception in Advanced Stage Non-Small Cell Lung Cancer. Am J Clin Oncol<\/em>. 2016;39(2):126-131. PMID 24632817<\/a><\/p>\n\n\n\n

41. Schroeder MC, Tien YY, Wright K, Halfdanarson TR, Taher Abu Hejleh<\/strong>, Brooks JM. Geographic variation in the use of adjuvant therapy among elderly patients with resected non-small cell lung cancer. Lung Cancer<\/em>. 2016;95:28-34. PMID 27040848<\/a><\/p>\n\n\n\n

42. Raman R, Deorah S, McDowell BD, Taher Abu Hejleh<\/strong>, Lynch CF, Gupta A. Changing incidence of esophageal cancer among white women: analysis of SEER data (1992-2010). Contemp Oncol (Pozn)<\/em>. 2015;19(4):338-340. PMID 26557784<\/a><\/p>\n\n\n\n

43. Clamon GH, Bossler AD, Taher Abu Hejleh<\/strong>, Furqan M. Germline mutations predisposing to non-small cell lung cancer. Fam Cancer<\/em>. 2015;14(3):463-469. PMID 25813228<\/a><\/p>\n\n\n\n

44. Schroeder MC, Lynch CF, Taher Abu Hejleh<\/strong>, Chrischilles EA, Thomas A. Chemotherapy use and surgical treatment by receptor subtype in node-negative T1a and T1b female breast cancers, Iowa SEER Registry, 2010 to 2012. Clin Breast Cancer<\/em>. 2015;15(1):e27-34. PMID 25245424<\/a><\/p>\n\n\n\n

45. Leon-Ferre RA, Taher Abu Hejleh<\/strong>, Halfdanarson TR. Extravasation of oxaliplatin into the mediastinum: a case report and review of the literature. Clin Adv Hematol Oncol<\/em>. 2012;10(8):546-548. PMID 23073056<\/a><\/p>\n\n\n\n

46. Taher Abu Hejleh<\/strong>, Mezhir JJ, Goodheart MJ, Halfdanarson TR. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. Curr Oncol Rep<\/em>. 2012;14(4):277-284. PMID 22532266<\/a><\/p>\n\n\n\n

47. Taher Abu Hejleh<\/strong>, Deyoung BR, Engelman E, Deutsch JM, Zimmerman B, Halfdanarson TR, Berg DJ, Parekh KR, Lynch WR, Iannettoni MD, Bhatia S, Clamon G. Relationship between HER-2 overexpression and brain metastasis in esophageal cancer patients. World J Gastrointest Oncol<\/em>. 2012;4(5):103-108. PMID 22645633<\/a><\/p>\n\n\n\n

48. Taher Abu Hejleh<\/strong>, Clamon G. Advances in the systemic treatment of leptomeningeal cancer. Clin Adv Hematol Oncol<\/em>. 2012;10(3):166-170. PMID 22402424<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

1. Abdeljalil RA, Al-Odwan A, Alshwayyat S, Nemrawi LO, Taher Abu Hejleh, Alrabi K, Yaser S, Jazar HA, Khader J, Al-Nsour A, Haddad H, Jalil RA. Multimodality approach for locally…<\/p>","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-22899","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/drtaherabuhejleh.com\/ar\/wp-json\/wp\/v2\/pages\/22899","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drtaherabuhejleh.com\/ar\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/drtaherabuhejleh.com\/ar\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/drtaherabuhejleh.com\/ar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/drtaherabuhejleh.com\/ar\/wp-json\/wp\/v2\/comments?post=22899"}],"version-history":[{"count":4,"href":"https:\/\/drtaherabuhejleh.com\/ar\/wp-json\/wp\/v2\/pages\/22899\/revisions"}],"predecessor-version":[{"id":22929,"href":"https:\/\/drtaherabuhejleh.com\/ar\/wp-json\/wp\/v2\/pages\/22899\/revisions\/22929"}],"wp:attachment":[{"href":"https:\/\/drtaherabuhejleh.com\/ar\/wp-json\/wp\/v2\/media?parent=22899"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}